Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity

Cancer Immunology, Immunotherapy

Volumn 56, Issue 8, 2007, Pages 1285-1297

  Mattarollo, Stephen R ^a,c   Kenna, Tony ^a   Nieda, Mie ^b   Nicol, Andrew J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Medinet Co Ltd   (Japan)

^c GREENSLOPES PRIVATE HOSPITAL   (Australia)

Author keywords

T cells; Antitumour; Bisphosphonate; Cancer; Chemotherapy; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GAMMA INTERFERON; PERFORIN; VINCRISTINE; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; DRUG TARGETING; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; PRIORITY JOURNAL; SENSITIZATION; SOLID TUMOR; T LYMPHOCYTE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; BURKITT LYMPHOMA; CARCINOMA; CELL LINE, TUMOR; CISPLATIN; COLORECTAL NEOPLASMS; CONCANAVALIN A; CYTOTOXICITY, IMMUNOLOGIC; DIPHOSPHONATES; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ETOPOSIDE; FEMALE; GENES, T-CELL RECEPTOR DELTA; GENES, T-CELL RECEPTOR GAMMA; HUMANS; IMIDAZOLES; INTERFERON TYPE II; LOVASTATIN; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASMS; PORE FORMING CYTOTOXIC PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; URINARY BLADDER NEOPLASMS; VINCRISTINE;

EID: 34248219009     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0279-2     Document Type: Article

References (55)

1. Baird RD, Kaye SB (2003) Drug resistance reversal - are we getting closer? Eur J Cancer 39(17):2450-2461
2. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727-729
3. Bonneville M, Fournie JJ (2005) Sensing cell stress and transformation through Vgamma9Vdelta2 T cell-mediated recognition of the isoprenoid pathway metabolites. Microbes Infect 7(3):503-509
4. Carding SR, Egan PJ (2002) Gammadelta T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2(5):336-345
5. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Raera C, Seaman J, Skerjanec A (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharm 42:1228-1236
6. Chien Y, Bonneville M (2006) Gamma delta T cell receptors. Cell Mol Life Sci 63:2089-2094
7. Clezardin P, Ebetino FH, Fournier PG (2005) Bisphosphonates and cancer-induced bone disease: beyond their anti-resorptive activity. Cancer Res 65(12):4971-4974
8. Conti L, Casetti R, Cardone M, Varano B, Martino A, Belardelli F, Poccia F, Gessani S (2005) Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J Immunol 174(1):252-260
9. Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E, Bonneville M, Jotereau F (2005) V gamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol 175(8):5481-5488
10. Coxon FP, Thompson K, Rogers MJ (2006) Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6:1-6
11. Dalton JE, Howell G, Pearson J, Scott P, Carding SR (2004) Fas-Fas ligand interactions are essential for the binding to and killing of activated macrophages by gamma delta T cells. J Immunol 173(6):3660-3667
12. Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies M, Bukowski JF (2001) MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 15:83-93
13. Das H, Wang L, Kamath A, Bukowski JF (2001) Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98(5):1616-1618
14. Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JC, Brown R, Ehmann WC, Schulman P, Frankel SR, De Angelo D, Scheinberg D (2005) Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 23(18):4110-4116
15. Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR (2002) Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 23(1):14-18
16. Garcia VE, Sieling PA, Gong GH, Barnes PF, Uyemura K, Tanaka Y, Bloom BR, Morita CT, Modlin RL (1997) Single cell analysis of gammadelta T cell response to nonpeptide mycobacterial antigens. J Immunol 159:1328-1335
17. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G (2003) Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197(2):163-168
18. Green AE, Lissina A, Hutchinson SL, Hewitt RE, Temple B, James D, Boulter JM, Price DA, Sewell AK (2004) Recognition of nonpeptide antigens by human Vgamma 9Vdelta 2 T cells requires contact with cells of human origin. Clin Exp Immunol 136:472-482
19. Green JR (2003) Antitumor effects of bisphosphonates. Cancer Suppl 97(3):840-847
20. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T (1999) Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 96(12):6879-6884
21. Huber SA (2000) T cells expressing the gamma delta T cell receptor induce apoptosis in cardiac myocytes. Cardiovasc Res 45(3):579-587
22. Kabelitz D, Wesch D, Pitters E, Zoller M (2004) Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol 173(11):6767-6776
23. Kabelitz D, Wesch D, Pitters E, Zoller M (2004) Potential of human gammadelta T lymphocytes for immunotherapy of cancer. Int J Cancer 112(5):727-732
24. Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minato N (2001) Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens. J Immunol 167(9):5092-5098
25. + T cell-mediated cytotoxicity. J Immunol 162:2639-2647
26. Knight LA, Conroy M, Fernando A, Polak M, Kurbacher CM, Cree IA (2005) Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay. Anticancer Drugs 16(9):969-976
27. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96(2):384-392
28. Kunzmann V, Wilhelm M (2005) Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma 46(5):671-680
29. Lafont V, Liautard J, Sable-Teychene M, Sainte-Marie Y, Favero J (2001) Isopentenyl pyrophosphate, a mycobacterial non-peptidic antigen, triggers delayed and highly sustained signaling in human gamma delta T lymphocytes without inducing down-modulation of T cell antigen receptor. J Biol Chem 276(19):15961-15967
30. Lake RA, Robinson BWS (2005) Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5:397-405
31. Lang F, Peyrat MA, Constant P, Davodeau F, David-Ameline J, Poquet Y, Vie H, Fournie JJ, Bonneville M (1995) Early activation of human V gamma 9V delta 2 T cell broad cytotoxicity and TNF production by nonpeptidic mycobacterial ligands. J Immunol 154(11):5986-5994
32. Lieberman J (2003) The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 3(5):361-370
33. Linck D, Lentini G, Tiemann M, Fauser AA, Parwaresch R, Basara N (2005) Sequential application of chemotherapy and monoclonal CD20 antibody: successful treatment of advanced composite-lymphoma. Leuk Lymphoma 46(2):285-288
34. Liu Z, Guo BL, Gehrs BC, Nan L, Lopez RD (2005) Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J Urol 173(5):1552-1556
35. Lopez RD (2002) Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases. Immunol Res 26(1-3):207-221
36. Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, Foglietta M, Palumbo A, Coscia M, Castella B, Bruno B, Bertieri R, Boano L, Boccadoro M, Massaia M (2005) Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 19(4):664-670
37. Matsumoto S, Kimura S, Segawa H, Kuroda J, Yuasa T, Sato K, Nogawa M, Tanaka F, Maekawa T, Wada H (2005) Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47:31-39
38. Mattarollo SR, Kenna T, Nieda M, Nicol AJ (2006) Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to Valpha24(+) NKT cell-mediated cytotoxicity. Int J Cancer 119(7):1630-1637
39. Mattarollo SR, Kenna T, Nieda M, Nicol AJ (2006) Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to Valpha24(+) NKT cell-mediated cytotoxicity. Int J Cancer 119:1630-1637
40. Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC (2003) Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 17(6):1068-1077
41. Neville-Webbe HL, Evans CA, Coleman RE, Holen I (2006) Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumor Biol 27:92-103
42. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113:364-371
43. Podack ER, Lowrey DM, Lichtenheld M, Hameed A (1988) Function of granule perforin and esterases in T cell-mediated reactions. Components required for delivery of molecules to target cells. Ann N Y Acad Sci 532:292-302
44. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T (2005) Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol 175(4):2144-2151
45. Rosen LS (2002) Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors. Semin Oncol 6(Suppl 21):28-32
46. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100(12):2613-2621
47. Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kuroda J, Nogawa M, Yuasa T, Kiyono Y, Wada H, Maekawa T (2005) Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 116(1):94-99
48. Scotet E, Martinez LO, Grant E, Barbaras R, Jeno P, Guiraud M, Monsarrat B, Saulquin X, Maillet S, Esteve JP, Lopez F, Perret B, Collet X, Bonneville M, Champagne E (2005) Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22(1):71-80
49. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783-792
50. Spada FM, Grant EP, Peters PJ, Sugita M, Melian M, Leslie DS, Lee HK, van Donselaar E, Hanson DA, Krensky AM, Majdic O, Porcelli SA, Morita CT, Brenner MB (2000) Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity. J Exp Med 191(6):937-948
51. Ullen A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kalkner KM, Lennernas B, Nilsson S (2005) Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncologica 44:644-650
52. Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, Caignard A (2005) Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol 174(3):1338-1347
53. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruedier T, Tony H-P (2003) Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102(1):200-206
54. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP (2003) Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102(1):200-206
55. Zgani I, Menut C, Seman M, Gallois V, Laffont V, Liautard J, Liautard JP, Criton M, Montero JL (2004) Synthesis of prenyl pyrophosphonates as new potent phosphoantigens inducing selective activation of human Vgamma9Vdelta2 T lymphocytes. J Med Chem 47(18):4600-4612